Mango: Reinventing Microbial QC for the Next Generation of Biomanufacturing

How do you modernize one of the slowest, most manual processes in pharmaceutical manufacturing? Join Mango CEO Simon Nielsen for a deep dive into how the company is building the next generation of microbial quality control — combining advanced hardware, AI-driven analysis, and automation-ready workflows to dramatically reduce time-to-result and enable automated manufacturing.

Mango’s technology builds on the ePetri platform and proprietary innovations designed to deliver the fastest time-to-result of any growth-based microbial detection system while generating rich datasets optimized for machine learning. The result is a new approach to microbial QC that integrates seamlessly with automated manufacturing environments and next-generation biologics production.

In this session, we explore Mango’s roadmap from its initial bioburden solution to a full MQC platform that supports sterility testing, environmental monitoring, and automated quality workflows. We also discuss the company’s strategy for scaling adoption across leading pharma manufacturers and enabling faster, safer production of advanced therapies including cell and gene therapies.

This session is designed for biotech and pharma leaders, manufacturing and quality teams, and investors interested in how automation, AI, and new technology are reshaping biomanufacturing infrastructure.

Guest Speaker Simon Nielsen — CEO, Mango

Moderated by: David Fleck, Founder & Managing Partner, Freeflow Ventures and Kevin Barrett, Managing Partner, Freeflow Ventures